• Conservative Treatments of Retinoblastoma

  NCT02866136

  Active, not recruitingInterventionalPhase 2Updated Nov 24, 2025
• A Prospective International Multicenter Clinical Trial for Eyes With Relapsed Retinoblastoma

  NCT04455139

  TerminatedInterventionalPhase 2Updated Oct 3, 2023
• A Study of the Effectiveness of a Local Injection of Chemotherapy for Retinoblastoma

  NCT00857519

  CompletedInterventionalNot ApplicableUpdated Dec 12, 2016
• Topotecan and Melphalan for Retinoblastoma

  NCT04799002

  RecruitingInterventionalPhase 3Updated Mar 16, 2021
• A Study to Give Treatment Inside the Eye to Treat Retinoblastoma

  NCT05504291

  RecruitingInterventionalPhase 2Updated Aug 25, 2026
• Study of Treatment for Patients With Cancer of the Eye -Retinoblastoma

  NCT00186888

  CompletedInterventionalPhase 3Updated Sep 4, 2025

ClinicalTrials.gov ID

NCT04681417

Lead Sponsor

Institut CurieOTHER

Overall Status

Recruiting

Study Type

Interventional

Phase

Phase 2Phase 3

Enrollment

225Estimated

Last Update Posted

Nov 28, 2025Actual

Start Date

Mar 25, 2021Actual

Primary Completion Date

Jan 20, 2035Estimated

Completion Date

Jan 20, 2036Estimated

Official Title

Ocular Conservative Treatment for Retinoblastoma: Efficacy of the New Management Strategies and Visual Outcome - RETINO 2018

Brief Summary

This protocol includes 2 independent studies. Both studies are multicenter studies, evaluating different therapeutic approaches in two different populations of patients:

• Study 1, a randomized phase-II study evaluating the efficacy of Intra-Arterial Chemotherapy (IAC) with melphalan and topotecan versus melphalan alone, both in association with ophthalmologic treatments.
• Study 2, a minimally invasive interventional study evaluating the results on visual function following reference treatment with intravenous (IV) chemotherapy in association with ophthalmologic or local ophthalmological treatment without IV chemotherapy.

Detailed Description

Primary objective of the studies:

• Study 1: To evaluate the efficacy of IAC in term of local control of the disease in patients eligible for IAC (randomized phase II study);
• Study 2: To assess the visual function, based on World Health Organization (WHO) criteria, in patients eligible for other conservative treatments (IV chemotherapy in association with local ophthalmologic trématent or local ophthalmological treatment without IV chemotherapy; this is a minimally invasive interventional study).

• Retinoblastoma

• Melphalan or Melphalan + Topotecan
• etoposide, carboplatin and vincristine or local ophthalmological treatment without IV chemotherapy
• Carboplatin administered on Day 1
• Thermotherapy (local treatment)
• Cryotherapy (local treatment)
• Iodine-125 plaques (local treatment)
• Intravitreal Melphalan chemotherapy injections (local treatment)

Ages Eligible for Study

Child (0-17)

Sexes Eligible for Study

All

Accepts Healthy Volunteers

No

Eligibility Criteria

Inclusion Criteria:

Overall study inclusion criteria:

1. Newly diagnosed retinoblastoma (RB).
2. Retinoblastoma with at least one eye eligible for conservative management.
3. Patients likely to be compliant with the study requirements and visits, including late follow-up.
4. Patients not previously treated with chemotherapy or radiotherapy for this or any other cancer.
5. Patients with no contraindication to the proposed treatments.
6. Informed consent signed by parents or legal representative.
7. French Social Security System coverage.

Study 1 inclusion criteria:

8.1. Children aged from 6 months to 6 years. 9. Retinoblastoma in at least one eye, deemed manageable with IAC in one side and without IV chemotherapy:

1. Unilateral Retinoblastoma classified as group B, C (if vitreous seeds < 3 mm), D or E with no invasion of the anterior segment, and without massive tumor of more than 2/3 of the eye, eligible for conservative management, or
2. Bilateral Retinoblastoma but with very unbalanced lesions between the two eyes: one eye group D or E without invasion of the anterior segment or massive tumor of more than 2/3 of the eye, eligible for IAC, and the other eye eligible for local treatment only (without IAC).

Study 2 inclusion criteria:

8.2. Retinoblastoma eligible for conservative management although not manageable with IAC:

1. Unilateral Retinoblastoma in children below 6 months of age, classified as Group A, B, C or D, with or without vitreous seeding, compatible with conservative management, or
2. Bilateral Retinoblastoma classified as group A, B, C D, or E without invasion of the anterior segment, and/or massive tumors of more than 2/3 of the eye and eligible for conservative management.

Exclusion Criteria:

Overall study non-inclusion criteria:

1. RB not eligible for conservative management :

   1. Extra-ocular extension of the disease, or
   2. Group E eyes with invasion of the anterior segment, and/or massive tumors of more than 2/3 of the eye.

2. Patient older than 6 years of age.

3. Patients with another associated disease contra indicating systemic chemotherapy.

4. Previously treated retinoblastoma by chemotherapy.

5. Patients already treated for another malignant disease.

6. Patient with any psychological, familial, sociological or geographical condition potentially hampering compliance with the study protocol and follow-up schedule.

7. Patients whose parents have not accepted the treatment regimen after explanation of it.

8. Contraindication to study drug mentioned in SmPC (Summary of Products Characteristics) of the study drugs.

9. Inclusion in another experimental anti-cancer drug therapy.

   Study 1 non-inclusion criteria:

10. Any contraindication or concomitant disease that would preclude the Study 1 treatment procedure and could delay treatment.

These patients should be eligible for Study 2.

Primary Purpose

Treatment

Allocation

Randomized

Interventional Model

Parallel Assignment

Masking

None (Open Label)

Lead Sponsor

Institut CurieOTHER

Collaborators

Fondation Rothschild ParisOTHER

camille.khanfard@chu-amiens.fr+33(0)322087650

bodet-d@chu-caen.fr+33(0)231064488